Immatics NV (IMTX) FinancialsIMTXImmatics NV

Evaluating the bottom line, Immatics N.V. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -734.95%, while the net margin is -683.42%. These profitability ratios, combined with a Return on Equity (ROE) of -47.80%, provide a clear picture of how effectively IMTX converts its operational activities into shareholder value.

In the context of the broader market, IMTX competes directly with industry leaders such as HROW and CGEM. With a market capitalization of $1.40B, it holds a significant position in the sector. When comparing efficiency, IMTX's gross margin of 100.00% stands against HROW's 71.27% and CGEM's N/A. Such benchmarking helps identify whether Immatics N.V. is trading at a premium or discount relative to its financial performance.

Immatics has a gross margin of 100%, but it has faced significant net losses, with a net income of -€62.49 million in Q2 2026. The company is currently in a phase of raising funds to support its clinical-stage projects, which could enhance its financial stability in the long term.